ABBV CLS 7262 is Being Evaluated as a Potential Treatment for Vanishing White Matter Disease in the Brain

The safety, pharmacokinetics (absorption), and tolerability of the investigational eIF2B activator ABBV-CLS-7262 is being evaluated in a Phase 1b clinical study to treat patients with Vanishing White Matter (VWM) Disease.…

Continue Reading ABBV CLS 7262 is Being Evaluated as a Potential Treatment for Vanishing White Matter Disease in the Brain